When pressure hits, your method needs to move along with it. SCIEX capillary electrophoresis (CE) solutions can keep your lab steady while flexing to meet the edge of innovation. Think trusted workflows, sharper resolution, and serious performance.

Adopting a new analytical platform in biopharmaceutical development requires thorough due diligence, including a comprehensive investigation of the platform's performance, reliability, and robustness. Equally important is assessing how the new platform compares to existing instrumentation in terms of data comparability and equivalency. These assessments are typically evaluated in protocols, such as method transfers or bridging studies. CE-SDS is the industry standard assay for assessing protein purity, integrity, and stability of biotherapeutics. With increased pressure to accelerate drug development timelines, there is a need to increase the throughput of this critical workflow.

SCIEX CE has been providing a solution for CE-SDS analysis for 35 years. You already know what works, now push it further. Download our content to learn more about the considerations needed to shift from the single capillary PA 800 Plus system to the multi-capillary BioPhase 8800 system and increase throughput without disrupting your operation:  

  • [Case study] Discover how Teva Pharmaceuticals demonstrates data equivalency for CE-SDS in the analytical development lab
  • [Whitepaper] Learn more about the differences between the single capillary PA 800 Plus system and the multi-capillary BioPhase 8800 system, and how to demonstrate equivalency with improved optics and throughput
  • [Webinar] Dig deeper into the Teva case study, with a more in-depth discussion on showing data equivalency
  • [Journal publication] Learn how Biogen approaches the move to the BioPhase 8800 system through bridging studies
  • [Panel discussion] Explore the common problems associated with CE-SDS optimization and how your peers tackle these issues

Access now

Request information